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The capacity of the immune system to adapt to
rapidly evolving viruses is a primary feature of
effective immunity, yet its molecular basis is
unclear. Here, we investigated protective HIV-1-
specific CD8+ T cell responses directed against the
immunodominant p24 Gag-derived epitope KK10
(KRWIILGLNK263-272) presented by human leukocyte
antigen (HLA)-B*2705. We found that cross-reactive
CD8+ T cell clonotypes were mobilized to counter
the rapid emergence of HIV-1 variants that can
directly affect T cell receptor (TCR) recognition.
These newly recruited clonotypes expressed TCRs
that engaged wild-type and mutant KK10 antigens
with similar affinities and almost identical docking
modes, thereby accounting for their antiviral efficacy
in HLA-B*2705+ individuals. A protective CD8+ T cell
repertoire therefore encompasses the capacity to
control TCR-accessible mutations, ultimately driving
the development of more complex viral escape vari-
ants that disrupt antigen presentation.
INTRODUCTION
Adaptive CD8+ T cell immunity is critical for protection against
viruses and other intracellular pathogens. At the molecular level,
this host-pathogen conflict centers on T cell receptor (TCR)engagement of major histocompatibility complex class I
(MHC-I) molecules bearing peptide fragments derived from the
intracellular invader. The ab TCR repertoire encompasses
a phenomenal level of diversity, which is generated by somatic
recombination of variable (V), diversity (D), and joining (J)
gene segments, junctional modifications, and differential
pairing of a and b chains. Theoretically, between 1015 and 1020
different TCRs can be generated by this process (Davis and
Bjorkman, 1988; Lieber, 1991). However, because of size
constraints and thymic selection, each individual harbors a reper-
toire estimated to contain around 2.5 3 107 TCRs (Arstila et al.,
1999). The diversity of the peripheral TCR repertoire has
profound implications for effective immune coverage (Nikolich-
Zugich et al., 2004).
Rapidly evolving pathogens capable of intrahost evolution
during the course of infection must contest with the array of
TCRs available for deployment. This sets the stage for a ‘‘molec-
ular arms race’’ between the pathogen and the host. Immune
escape bymutation of targeted CD8+ T cell epitopes is a cardinal
feature of HIV-1 infection and represents a key obstacle to the
successful development of an AIDS vaccine (Goulder and Wat-
kins, 2004). Indeed, the intense antiviral pressure exerted by
CD8+ T cell responses drives the rapid selection of escapemuta-
tions from the earliest stages of infection (Goonetilleke et al.,
2009). Eventually, the frequency of such mutations correlates
with the prevalence of the restricting human leukocyte antigen
(HLA) class I allele across the population as a whole (Dong
et al., 2011; Kawashima et al., 2009; Moore et al., 2002). None-
theless, certain HLA class I alleles, including HLA-B*27, can
confer relative protection from disease progression (Kaslow
et al., 1996). InHLA-B*27+ individuals infectedwithHIV-1cladeB,Immunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc. 425
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p24 Gag is almost invariably targeted by CD8+ T cells (Altfeld
et al., 2006; Scherer et al., 2004). These KK10-specific CD8+
T cells unleash potent effector functions (Almeida et al., 2007;
Berger et al., 2011), and the conservation of this response is
thought to account for the benefits conferred by HLA-B*27
expression.
A number of mutations in the KK10 epitope have been
reported in HIV-1-infected patients. The commonly observed
Leu268Met mutation was initially considered to be a compensa-
tory change required for the later appearance of the Arg264Lys
mutation, which is associated with increased viral loads and clin-
ical progression (Ammaranond et al., 2011; Feeney et al., 2004;
Goulder et al., 1997; Kelleher et al., 2001). However, we recently
showed that the Leu268Met mutation enables HIV-1 to evade
recognition by highly effective CD8+ T cells, including clonotypes
defined by the expression of public TRBV4-3 TRBJ1-3 TCRs,
which can be shared between individuals responding to the
KK10 epitope (Iglesias et al., 2011). Nonetheless, control of viral
replication is usually preserved despite this mutation. In HIV-1-
infected patients presenting primarily a Leu268Met virus, the
KK10-specific CD8+ T cell response seems to be more reactive
against the Leu268Met variant compared to the wild-type (WT)
epitope; the converse applies in patients presenting a predomi-
nant WT virus (Iglesias et al., 2011; Lichterfeld et al., 2007;
Streeck et al., 2008). These observations suggest that the
immune response can adapt to mutations within the KK10
peptide that remain accessible to the TCR repertoire. However,
the precise mechanism responsible for the maintenance of
immune control in this situation remains unclear. Here, we
show that the immune system can counter the emergence of
Leu268Met variants through the mobilization of newly generated
cross-reactive KK10-specific CD8+ T cells, in particular those
bearing TRBV6-5 TRBJ1-1 TCRs. These clonotypes were able
to control both WT and Leu268Met viruses and retained potent
suppressive capacity unless the virus succeeded in acquiring
mutations, such as Arg264Lys, that negatively impact epitope
presentation.
RESULTS
Emergence of Cross-Reactive WT and Leu268Met
KK10-Specific CD8+ T Cells during Primary HIV-1
Infection
To understand how KK10-specific CD8+ T cell populations
adjust to the early emergence of the Leu268Met mutant and
maintain control of viral replication, we examined the fine
specificity of responses to this epitope in HLA-B*2705+ patients
with primary HIV-1 infection. For this purpose, WT, Leu268Met,
or dually reactive KK10-specific CD8+ T cells were identified
directly ex vivo by flow cytometry with fluorescent HLA-
B*2705-peptide tetramers (Figure 1A). During early infection
(i.e., within 3 months of viral transmission), robust CD8+ T cell
responses against WT, but not Leu268Met, KK10 could be de-
tected in three patients (Figures 1A and 1B). These CD8+ T cell
populations engaged WT KK10 antigen (Ag) with high avidity,
as revealed by staining with the corresponding CD8-null
tetramer. Previous studies have shown that this physical param-
eter correlates with potent HIV-suppressive capacity (Almeida426 Immunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc.et al., 2007, 2009; Berger et al., 2011). Subsequently, we
observed CD8+ T cell expansions with reactivity against
the Leu268Met variant (Figures 1A and 1B). These distinct
populations exhibited high avidities for the cognate Ag in
two patients (PrInf A and B) with stable control of viral replication
in the absence of antiretroviral therapy. In contrast, lower-
avidity Leu268Met KK10-specific CD8+ T cells were present in
patient PrInf C, who initiated antiretroviral therapy 18 months
after infection as a result of progressively increasing viral loads
(Figure 1C).
Extensive viral sequencing, from both plasma and peripheral
bloodmononuclear cells, was conducted to inform the observed
patterns of KK10 reactivity (Figure 1C and Table S1 available
online). In PrInf C, expansion of the Leu268Met KK10-specific
CD8+ T cell population coincided with the emergence of
detectable Leu268Met variant virus at month 18. Indeed, the
Leu268Met sequence was dominant at the cell-associated
DNA level, indicating that the corresponding variant virus was
poorly controlled in this patient. In patients PrInf A and B, how-
ever, the high-avidity Leu268Met KK10-specific CD8+ T cell
populations expandedwithout evidence of the Leu268Metmuta-
tion. Indeed, the Leu268Met sequence was detected in the cell-
associated DNA from PrInf A only at a very late time point, after
the initiation of antiretroviral therapy. Collectively, these data
indicate that the immune system can generate high-avidity
cross-reactive WT and Leu268Met KK10-specific CD8+ T cells
soon after primary HIV-1 infection, even with frequencies of
Leu268Met variant virus that lie below the limit of detection
with conventional sequencing methodologies.
High-Avidity WT and Leu268Met KK10-Specific CD8+
T Cells Incorporate TRBV6-5 TRBJ1-1 Motif-Bearing
TCRs
To characterize the molecular basis for WT and Leu268Met
cross-reactivity at the level of TCR usage, we performed
ex vivo analyses of TRB gene expression in both WT and dually
reactive WT and Leu268Met KK10-specific CD8+ T cell popula-
tions (Figure 2). CD8+ T cell populations specific for the WT
epitope were characterized by the turnover of recurrent clono-
types, several of which used the TRBV4-3 gene as described
previously (Iglesias et al., 2011). In contrast, the WT and
Leu268Met KK10-specific CD8+ T cell populations comprised
entirely distinct clonotypes, suggesting de novo mobilization
from the naive pool. The high-avidity WT and Leu268Met
KK10-specific CD8+ T cells observed in patients PrInf A and
PrInf B showed particular enrichments for TRBV6-5 TRBJ1-1
clonotypes. Furthermore, TRBV6-5 TRBJ1-1 clonotypes were
detected in both WT and Leu268Met KK10-specific CD8+
T cell populations in two untreated HLA-B*2705+ patients during
the chronic phase of HIV infection (ChInf D and E; Figure S1A).
The CDR3b sequence differed by a maximum of three amino
acids between these TCRs (Figure 1D), indicating that a
TRBV6-5 TRBJ1-1 motif (CASRXGXGXTEAF) can underpin WT
and Leu268Met cross-reactivity. Of note, a similar CDR3b
sequence was recently detected in an HIV-1-infected patient
with elite control of viral replication (Chen et al., 2012). Molecular
analysis of TRA gene expression revealed that the TRBV6-5
TRBJ1-1 clonotypes were accompanied by TRAV14 TRAJ21
transcripts in the respective CD8+ T cell populations from PrInf
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Figure 1. Ex Vivo Analysis of WT and Leu268Met KK10-Specific CD8+ T Cells
(A) Simultaneous WT and Leu268Met HLA-B*2705-KK10 tetramer staining of PBMCs from one HIV-1-infected patient (PrInf A) during and after primary infection.
CD8+ T cells were stained with standard (Std) tetramers (top) and CD8-null tetramers (bottom); the latter selectively identify high-avidity cells. The percentages
and flow cytometric sorting gates for WT versus Leu268Met or WT and Leu268Met KK10-specific tetramer+CD8+ T cell populations are shown.
(B) Kinetics ofWT versus Leu268Met orWT and Leu268Met KK10-specific CD8+ T cell expansions in three patients (PrInf A, B, andC) fromprimary HIV-1 infection
onward. Standard and CD8-null tetramer+CD8+ T cells are shown.
(C) Plasma viral load measurements in three patients (PrInf A, B, and C) from primary HIV-1 infection onward. The Leu268/Met268 ratio within the KK10 epitope is
shown at two time points based on viral sequencing from plasma or cell-associated DNA.
(D) CDR3b amino acid sequence of TRBV6-5 TRBJ1-1 clonotypes within WT and Leu268Met KK10-specific CD8+ T cell populations from four HIV-1-infected
patients: PrInf A and B (24 and 18 months after primary infection, respectively) and ChInf D and E (chronic infection).
(E) CDR3a amino acid sequence of TRAV14 TRAJ21 transcripts within WT and Leu268Met KK10-specific CD8+ T cell populations from three HIV-1-infected
patients: PrInf A (24 months after primary infection) and ChInf D and E (chronic infection).
See also Table S1.
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Coadaptation of HIV and CD8+ T Cell ImmunityA and ChInf D (Figures 1E and S1B). Moreover, a subdominant
TRAV14 TRAJ21 sequence was detected in the Leu268Met
KK10-specific CD8+ T cell population in ChInf E. These data sup-
port a preferential pairing of TRBV6-5 TRBJ1-1 and TRAV14
TRAJ21 chains in KK10-specific CD8+ T cell clonotypes.
TRBV6-5 TRBJ1-1 Clonotypes Control WT and
Leu268Met Viruses Effectively
To evaluate the functional impact of WT and Leu268Met cross-
reactivity in more detail, we generated a CD8+ T cell clone
(C12C) bearing a TRBV6-5 TRBJ1-1 TRAV14 TRAJ21 TCR (Fig-
ure 3A). The functional properties of C12C were evaluated in
parallel with two other clones, one with high avidity specifically
for the WT KK10 epitope (E2C) and one with low avidity for the
same Ag (H8B); the latter clone was included to illustrate poor
CD8+ T cell efficacy in our assays (Iglesias et al., 2011). Both
WT and Leu268Met HLA-B*2705-KK10 tetramers costainedC12C, in contrast to E2C and H8B. Moreover, C12C stained
with the corresponding CD8-null tetramers, indicating high levels
of avidity for both the WT and Leu268Met epitopes (Figure 3B).
This highly avid dual recognition was reflected functionally in
cytolytic Cr51 release assays, with C12C demonstrating sensitive
responses to both forms of the epitope in peptide titrations (Fig-
ure 3C). To expand these findings, we measured degranulation
(CD107a mobilization) and the intracellular production of IFN-g,
TNF-a, IL-2, and MIP-1b by these clones in response to primary
HLA-B*2705+ CD4+ T cells infected with HIVNL4-3 viruses ex-
pressing either the WT or Leu268Met forms of the KK10 epitope
(Figure 3D). In addition, we assessed the elimination of HIV-in-
fected primaryHLA-B*2705+CD4+ target cells in vitro (Figure 3E).
In line with the previous results, C12C displayed a robust poly-
functional profile in the presence of either WT or Leu268Met
viruses and efficiently suppressed the replication of both HIV
strains in primary CD4+ T cells. These features have all beenImmunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc. 427
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Figure 3. Functional Characterization of the
CD8+ T Cell Clone C12C
(A) TCRb and TCRa amino acid sequences of the
C12C clone. This clone was derived from patient
ChInf D (Figure S1).
(B) Comparative stainings of three KK10-specific
CD8+ T cell clones (H8B, E2C, and C12C) with
WT or Leu268Met HLA-B*2705-KK10 tetramers
(standard or CD8 null). A pretitrated concentration
of each tetramer (0.1 mg/ml) was used to highlight
interclonal avidity differences.
(C) Antigen sensitivities (i.e., EC50 values in Cr
51
release assays) of the KK10-specific CD8+ T cell
clones H8B, E2C, and C12C.
(D) Polyfunctional profiles of H8B, E2C, and
C12C after incubation for 6 hr with primary
HLA-B*2705+CD4+ T cells infected with HIVNL4-3
viruses expressing either WT, Leu268Met, or the
compound Ser173Ala+Arg264Lys+Leu268Met
(SARKLM) mutation (CD8:CD4 ratio 10:1). The pie
charts depict the background-adjusted polyfunc-
tional profile of the CD8+ T cell clones. For
simplicity, responses are grouped according to
the number of functions elicited upon antigen
encounter; individual segments represent the
proportions of cells within each total clonal pop-
ulation that exhibited the number of functions
indicated. The following functions were assessed:
CD107a, IFN-g, TNF-a, IL-2, and MIP-1b. In the
bottom panel, representative stainings of primary
CD4+ T cells at day 3 postinfection with WT,
Leu268Met, or SARKLM HIVNL4-3 viruses are
shown to demonstrate that infection rates (intra-
cellular p24 expression) were equivalent in these
experiments.
(E) Suppression of HIV replication in primary HLA-
B*2705+CD4+ T cells infectedwithWT (black bars),
Leu268Met (white bars), or SARKLM (gray bars)
HIVNL4-3 viruses by H8B, E2C, and C12C at
different E:T ratios. An irrelevant clone (Irr.) with
specificity for an epitope derived from cytomega-
lovirus is shown as a negative control. The
percentage of p24+CD4+ T cells was measured by
flow cytometry at day 3 postinfection.
Representative data from three independent
experiments are shown.
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Coadaptation of HIV and CD8+ T Cell Immunitylinked with CD8+ T cell efficacy against HIV in vivo (Appay et al.,
2008).
Next, we assessed the impact of C12C on viral selection
in vitro. For this purpose, we cocultured target cells infected
with both ‘‘primary’’ and ‘‘emerging’’ viruses (e.g., WT and
Leu268Met HIVNL4-3 strains) together with CD8
+ T cell clones,
then sequenced the residual viral population (Figure S2). Ratios
of WT versus mutant virus were determined according to relative
peak height on the sequencing electrogram; this approach was
adapted to detect frequencies as low as 10% of the total viralFigure 2. Clonotype Usage in KK10-Specific CD8+ T Cell Populations f
TRBV and TRBJ usage, CDR3b amino acid sequence, and clonotype frequ
tetramer+CD8+ T cell populations isolated directly ex vivo from three patients (P
cytometric sorting gates are shown in Figure 1A. Recurrent clonotypes across ti
within this data set. See also Figure S1.population. Although the suppressive capacity of E2C was
evident in this assay (Figure 4A), the presence of this clone re-
sulted in selection of the Leu268Met mutant over the WT virus
(Figure 4C), consistent with the inability of E2C to recognize
the Leu268Met epitope. In contrast, H8B did not select for the
Leu268Met mutant because of its low avidity and poor HIV-
suppressive capacity (Figures 4A and 4C). Importantly, C12C
suppressed HIV replication efficiently in this assay without
selecting for the Leu268Met mutant. These results support our
previous observations in vivo that CD8+ T cells with high levelsrom Primary HIV-1 Infection Onward
ency are shown for WT and Leu268Met or dually reactive KK10-specific
rInf A, B, and C) during and after primary HIV-1 infection. Representative flow
me points within patients are color coded. Symbols denote public clonotypes
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Figure 4. Impact of Distinct CD8+ T Cell
Recognition Properties on Viral Selection
In Vitro
(A and B) p24 concentrations at day 7 post-
infection of 721.221-CD4-B*2705 cells with
WT and Leu268Met (A), WT and SARKLM, or
Leu268Met and SARKLM (B) viruses in the pres-
ence of the indicated CD8+ T cell clones.
(C and D) In vitro selection of viral mutants by
KK10-specific CD8+ T cell clones. Percentages
of WT and Leu268Met (C), WT and SARKLM, or
Leu268Met and SARKLM (D) viruses were deter-
mined at day 3 and day 7 postinfection of 721.221-
CD4-B*2705 cells cocultured in the presence of
the indicated CD8+ T cell clones.
Representative data from two independent ex-
periments are shown. See also Figure S2.
Immunity
Coadaptation of HIV and CD8+ T Cell Immunityof sensitivity for the WT KK10 epitope in isolation can drive the
emergence of early Leu268Met mutants (Iglesias et al., 2011).
Collectively, these data indicate that the generation of CD8+
T cells bearing TCRs with dual reactivity can enable the immune
system to counter the emergence of Leu268Met mutants.
HLA-B*2705 Recognition by a TRBV6-5 TRBJ1-1
Motif-Bearing TCR
To determine how TRBV6-5 TRBJ1-1motif-bearing TCRs cross-
recognize both the WT and Leu268Met epitopes, we expressed,
refolded, and purified the C12C TCR. Surface plasmon reso-
nance experiments showed that the C12C TCR bound both
WT and Leu268Met forms of HLA-B*2705-KK10 with equivalent
affinities (Kd1–5 mM) (Figure S3). This value falls at the high end
of the affinity range previously determined for TCR interactions
with MHC-I-peptide complexes (Bridgeman et al., 2012) and
concurs with the observed tetramer binding and functional prop-
erties (Figure 3). Next, we determined the high-resolution crystal
structures of the binary WT and Leu268Met HLA-B*2705-KK10
complexes and the corresponding ternary complexes with the
C12C TCR (Table 1).
The binary structures showed that the KK10 epitope bound to
HLA-B*2705 in a bulged and constrained conformation (Theo-
dossis et al., 2010), with the flexible central part of the peptide
protruding from the Ag-binding cleft (Figure 5A). The residues430 Immunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc.at P2, P3, P8, and P10 were buried in
the Ag-binding cleft, whereas the resi-
dues at P1, P4–P7, and P9 were solvent
exposed. The structure of the Leu268Met
HLA-B*2705-KK10 epitope was virtually
identical to that of the WT complex, with
a root mean square deviation (rmsd) of
0.06 A˚ and 0.15 A˚ for the Ag-binding cleft
and the peptide, respectively (data not
shown). Moreover, the Leu268Met muta-
tion did not affect HLA-B*2705-KK10
complex stability (Tm WT = 63.5C ±
0.5C, Tm Leu268Met = 64.0C ± 1.0C).
The C12C TCR docked at an angle
of 57 across the WT HLA-B*2705-KK10
Ag-binding cleft (Figures 5B and 5C)and adopted a typical bindingmode, with the Va and Vb domains
positioned over the a2 and a1 helices, respectively (Burrows
et al., 2010). Located toward the C-terminal end of the HLA-
B*2705-KK10 Ag-binding cleft, the C12C TCR formed a total
of 124 van der Waals (vdw) interactions and 16 hydrogen (H)
bonds with a total buried surface area (BSA) at the interface
of 1,860 A˚2 (Table S2), comprising contributions of 58%
and 42% from the Va and Vb domains, respectively. All six
CDR loops of the C12C TCR contributed to the interaction with
WT HLA-B*2705-KK10 (Figure 5C), albeit to varying degrees,
with the predominant contacts being made via the CDR2a,
CDR3a, and CDR3b loops (19.7%, 24.6%, and 19.8% of the
BSA, respectively). Notably, the center of mass of the C12C
TCR was shifted toward the a1 helix (77% of the HLA-B*2705
BSA), such that limited contacts were formed with the a2 helix
(23% of the HLA-B*2705 BSA). Ligation-induced structural
changes are described in Supplemental Information online
(Figure S4).
The CDR2a loop was the only region of the C12C TCR that
contacted the a2 helix of HLA-B*2705. Further, only two residues
(Glu154 and Gln155) of the a2 helix of HLA-B*2705 were con-
tacted by the C12C TCR, thereby representing the smallest
contribution by the a2 helix seen in any TCR-MHC-I-peptide
structure to date. In contrast, all six CDR loops of the C12C
TCR contacted the a1 helix (Table S2). Arg62 was surrounded
Table 1. Data Collection and Refinement Statistics
Data Collection Statistics C12C-HLA-B*2705KK10 C12C-HLA-B*2705L268M HLA-B*2705KK10 HLA-B*2705L268M
Space group P21 P21 P212121 P212121
Cell dimensions (A˚, ) 56.68, 70.32, 107.77; b = 98.77 57.41, 71.31, 109.57; b = 98.80 51.21, 82.33, 109.24 51.27, 82.35, 109.60
Resolution (A˚) 2.40 (2.53–2.40) 1.90 (2.00–1.90) 1.60 (1.69–1.60) 1.60 (1.69–1.60)
Total number of observations 243,277 (34,786) 255,452 (37,384) 438,464 (63,793) 409,890 (34,899)
Number of unique observations 32,993 (4,791) 68,882 (10,026) 61,797 (8,892) 55,998 (5,045)
Multiplicity 7.4 (7.3) 3.7 (3.7) 7.1 (7.2) 7.3 (6.9)
Data completeness (%) 100 (100) 99.8 (99.9) 100 (100) 90.5 (57.5)
I/sI 4.5 (1.8) 4.4 (1.6) 7.1 (2.8) 18.3 (4.8)
Rpim (%)
a 5.9 (16.3) 7.0 (27.4) 6.9 (23.6) 2.6 (13.9)
Refinement Statistics
Nonhydrogen Atoms
Protein 6792 6884 3269 3277
Water 337 486 585 458
Rfactor (%)
b 17.8 18.6 19.7 19.1
Rfree (%)
b 25.7 24.5 23.7 22.7
Rms Deviation from Ideality
Bond lengths (A˚) 0.008 0.006 0.006 0.006
Bond angles (o) 1.128 1.022 0.987 1.038
Ramachandran Plot (%)
Favored and allowed region 99.3 99.6 99.4 99.4
Generously allowed region 0.3 0.4 0.3 0.3
Disallowed region 0.4 0.0 0.3 0.3
Data collection and refinement statistics for the crystal structures of the binary WT and Leu268Met HLA-B*2705-KK10 complexes, as well as the cor-
responding ternary complexes with the C12C TCR, are indicated. Values in parentheses are for the highest-resolution shell.
aRpim = Sh [1(N1)]1 2 SijIi(h) – <I(h)> jShSi Ii (h), where I is the observed intensity and <I> is the average intensity of multiple observations from
symmetry-related reflections.
bRfactor = Shkl jjFojjFcjj Shkl jFoj for all data except approximately 5%, which were used for Rfree calculation.
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CDR3a loop contacted a more extensive region of the a1
helix (residues 62 to 69). The TCRb chain contacted a focused
region of the a1 helix (positions 72, 76, 79, and 83; Figure S5B).
The interactions between the germline-encoded CDR1b and
CDR2b loops were quite limited with respect to HLA-B*2705
binding (14.3% and 7.3% of the BSA, respectively), thereby sug-
gesting that the biased TRBV gene usage was attributable to
indirect mechanisms (Figure S6; Stadinski et al., 2011).
Viral Determinant Recognition by a TRBV6-5 TRBJ1-1
Motif-Bearing TCR
The WT KK10 peptide bulged centrally from the Ag-binding cleft
and was contacted by the CDR1a, CDR2a, CDR3a, and CDR3b
loops. Unlike the binary WT HLA-B*2705-KK10 structure, the
entire region of the peptide was clearly resolved in the ternary
complex, indicating that the conformation of the flexible peptide
determinant was stabilized and altered by TCR ligation, as
observed in other systems (Archbold et al., 2009; Tynan et al.,
2007). The C12C TCR pivoted on the P6-Leu residue, and addi-
tionally contacted residues P1, P4–P5, P7, and P9, thereby
ensuring broad coverage of the viral determinant. The CDR1a
and CDR2a loops were positioned over the N-terminal region
of the peptide contacting P1, P4, and P6, whereas the CDR3a
loop was centrally located contacting P4 and P6, and theCDR3b loop was situated more toward the C-terminal end of
the viral peptide contacting P6–P7 and P9 (Figure 5D). The
P1-Lys residuewasH-bonded toGln30a, whereas the backbone
of the CDR1a loop and Tyr59a from the CDR2a loop packed
against the N-terminal ‘‘slope’’ of the peptide. The CDR3b loop
was the only region of the TCRb chain that interacted with the
peptide, forming two H-bonds with P7-Gly and P9-Asn and
a series of vdw interactions. The majority of these interactions
involved Gly109b, Gly111b, and Thr113b, thereby providing
structural explanations for both the CDR3b motif and preferen-
tial TRBJ1-1 gene usage (Table S2). Importantly, P6-Leu was
sequestered fully by the C12C TCR. The P6-Leu side chain
protruded into a central, mostly hydrophobic, pocket that was
enveloped by all three CDRa loops and the CDR3b loop and sur-
rounded by a region of the CDR1amain chain, Phe113a, Tyr55a,
Arg107a, Gly111b, and Thr113b. Thus, P6-Leu represented the
central focal point of the C12C TCR.
The crystal structures of Leu268Met HLA-B*2705-KK10 in
isolation and in complex with the C12C TCR showed how the
P6-Leu-Met mutation was readily accommodated (Figure 5E).
The density of the central region of the Leu268Met peptide
was poorly defined in the binary structure, suggesting that the
epitope was intrinsically flexible regardless of the amino acid at
P6. The C12C TCR docked onto Leu268Met HLA-B*2705-
KK10 in essentially an identical manner to that of the cognateImmunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc. 431
Figure 5. Structure of the C12C TCR in
Complex with HLA-B*2705-KK10
(A) Cartoon representation of HLA-B*2705 with
KK10 in stick representation. The sphere repre-
sents the Ca atom of P7-Gly.
(B) Cartoon representation of the C12C TCR in
complex with HLA B*2705-KK10. The a chain of
the C12C TCR is colored in pale pink, with the
b chain in pale blue. The CDR1, 2, and 3 loops are
colored in purple, green, and yellow for TCRa and
blue, red, and orange for TCRb, respectively. The
HLA-B*2705 molecule is colored in white and the
KK10 epitope is represented in pink stick and
surface format.
(C) Footprint of the C12C TCR on the HLA-B*2705-
KK10 surface, colored by CDR loop contact as in
(B). The black spheres represent the center of
mass for the Va and Vb domains of the C12C TCR.
(D) Interaction between the KK10 epitope (pink
stick) and the C12C TCR loops. The spheres
represent the Ca atoms of the glycine residues.
The blue dashed lines represent vdw interactions
and the red dashed lines represent hydrogen
bonds.
(E) Superposition of the C12C TCR in complex
with WT and Leu268Met HLA-B*2705-KK10. The
peptides are represented in stick format and the
CDR loops are shown in cartoon.
See also Figures S3–S6.
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Coadaptation of HIV and CD8+ T Cell ImmunityWT interaction (rmsd 0.39 A˚), revealing that the mutation did not
cause a significant repositioning of the C12C TCR (Figure 5E).
Instead, P6-Met was located in the same pocket as P6-Leu
and formed very similar interactions. Thus, the C12C TCR was
perfectly adapted to cope with the P6-Leu-Met substitution, ex-
plaining the ability of the corresponding CD8+ T cell clone to
cross-recognize both WT and Leu268Met KK10 epitopes and
control the emergence of escape mutants.
TRBV6-5 TRBJ1-1 Motif-Bearing TCRs Are Not Readily
Generated by Somatic Recombination
Each of the observed TRBV6-5 TRBJ1-1 clonotypes was en-
coded by only one nucleotide sequence. Analysis of these nucle-
otide sequences showed that the core of the CASRXGXGXTEAF
motif was not predominantly germline encoded (Figure 6A). The
two conserved glycines at CDR3b positions 5 and 7 could be
completely attributed to the germline genes in only one of the
five TRBV6-5 TRBJ1-1 clonotypes. For the other four clono-432 Immunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc.types, only one of the two conserved
glycines was completely germline en-
coded, and therefore nucleotide addi-
tions were necessary to generate amino
acids in direct contact with the WT
or Leu268Met peptide (Table S2). In
contrast, multiple nucleotide sequences
with predominant germline encoding of
the associated motif have been observed
both within and across individuals for
TRBV4-3 TRBJ1-3 clonotypes, which
are commonly mobilized and recognize
only the WT form of the KK10 epitopewith high avidity (Iglesias et al., 2011). Moreover, the TRBV6-5
TRBJ1-1 clonotypes required significantly higher numbers of
nucleotide additions compared to the observed TRBV4-3
TRBJ1-3 clonotypes (Figure 6B). These observations suggested
that production efficiency for the observed TRBV6-5 TRBJ1-1
clonotypes was relatively low, at least compared to the observed
TRBV4-3 TRBJ1-3 TCRs. Thus, although the generation of
KK10-specific CD8+ T cells bearing WT and Leu268Met cross-
reactive TRBV6-5 TRBJ1-1 TCRs is an effective strategy to
combat the appearance of Leu268Met variants, it may be chal-
lenging for the immune system to achieve this adaptation.
Eventual Viral Escape from Cross-Reactive WT and
Leu268Met KK10-Specific CD8+ T Cells
Faced with TCR repertoire adaptation to viral variants, HIV
has developed further means to escape KK10-specific CD8+
T cell recognition, namely the Arg264* mutation. Arg264Lys is
the most frequently detected change, although Arg264Thr,
TRBV TRBJ
C A S R E G L G G T E A F
tgt gcc agc aga gag gga ctg ggg ggc act gaa gct ttc 9
--- --- --- aga gag gga ctg ggg ggc act --- --- --- 9
--- --- --- aga gag gga ctg ggg ggc act --- --- --- 9
C A S R E G Q G G T E A F
tgt gcc agc agg gag gga cag ggg ggc act gaa gct ttc 4
C A S R E G R G G T E A F
tgt gcc agc agg gag gga cgg ggg ggc act gaa gct ttc 7
--- --- --- agg gag gga cgg ggg ggc act --- --- --- 7
C A S R G G Q G S T E A F
tgt gcc agc agg ggg gga cag gga agt act gaa gct ttc 7
C A S R A G Q G A T E A F
tgt gcc agc agg gcc ggg cag ggg gca act gaa gct ttc 8
TRBV6-5 tgt gcc agc agt tac tc  
  tg aac act gaa gct ttc TRBJ1-1
n-additions
CDR3
              TRBD1: gggacagggggc   TRBD2: gggactagcggggggg /  gggactagcgggaggg
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Number of   Figure 6. Genetic Coding of KK10-Specific
TRBV6-5 TRBJ1-1 Clonotypes
(A) Shown are the observed nucleotide sequences
coding for the TRBV6-5 TRBJ1-1 clonotypes
described in this study, together with the contri-
butions from the TRBV (green), TRBD (orange),
and TRBJ (blue) genes that would require the
minimum number of nucleotide additions (black).
Potential P-additions are underlined. The multiple
lines per nucleotide sequence display the multiple
potential recombination events, i.e., different gene
contributions and nucleotide additions, that could
produce the observed nucleotide sequences with
the minimum number of nucleotide additions.
(B) Comparative analysis of the minimal number of
nucleotide additions required to generate the ob-
served nucleotide sequences coding for TRBV6-5
TRBJ1-1 clonotypes versus TRBV4-3 TRBJ1-3 clonotypes. The TRBV4-3 TRBJ1-3 clonotypes considered in this analysis were those observed in this
and previous studies (Iglesias et al., 2011). Statistical analysis was conducted the Mann-Whitney U-test. *p < 0.05.
Immunity
Coadaptation of HIV and CD8+ T Cell ImmunityArg264Gln, and Arg264Gly substitutions have also been ob-
served (Ammaranond et al., 2005; Betts et al., 2005; Feeney
et al., 2004; Goulder et al., 2001; Kelleher et al., 2001; Pillay
et al., 2005). The Arg264* mutation occurs at position 2 of the
KK10 epitope, which acts as an anchor for HLA-B*27. Accord-
ingly, the observed mutations at this position negatively affect
epitope presentation via dramatic reductions in MHC-I-peptide
binding affinity, which lead to decreased complex stability on
the cell surface and impaired peptide loading during endoge-
nous Ag processing (Ammaranond et al., 2005; Goulder et al.,
1997, 2001). However, this mutation also impacts p24 structure
and function; consequently, the Ser173Ala compensatory muta-
tion is necessary to restore viral fitness (Schneidewind et al.,
2007, 2008). The necessity for two discrete and simultaneous
mutations represents a major constraint for the virus and has
been proposed as an explanation for the late emergence of
Arg264Lys mutants. Nonetheless, the eventual appearance of
the Arg264Lys mutation abrogates the efficacy of KK10-specific
CD8+ T cells. None of the tested clones, including C12C, were
able to suppress replication of a virus displaying the Ser173Ala,
Arg264Lys, and Leu268Met mutations (SARKLM) (Figure 3E) or
display polyfunctional profiles in the presence of primary HLA-
B*2705+ CD4+ cells infected with SARKLM HIVNL4-3 (Figure 3D).
Furthermore, although both C12C and E2Ccould drive the selec-
tion of the SARKLM mutant against WT virus in vitro, only the
WT and Leu268Met cross-reactive clone C12C selected the
SARKLM mutant against Leu268Met virus (Figures 4B and 4D).
These data are consistent with the notion that SARKLM
represents the ultimate escape virus and suggest that immune
adaptation to Leu268Met, the early clonotype-specific escape
mutant, drives the loss of KK10 binding to eliminate the possi-
bility of further recognition by CD8+ T cells.
DISCUSSION
Viral escape from CD8+ T cell recognition is a hallmark of HIV-1
infection. The first escape variants can replace the original
founder virus sequence within days and, as a consequence of
ongoing immune pressure, sequential mutations follow (McMi-
chael et al., 2010). Our data highlight the complex balance
between viral evolution and immune adaptation focused ona single immunodominant epitope. In the context of HLA-
B*2705, the early emergence of Leu268Met mutants is driven
by high-avidity CD8+ T cell clonotypes specific for the WT
KK10 epitope (Iglesias et al., 2011). The Leu268Met substitution
diminishes TCR recognition by these clonotypes, without cost to
viral fitness. For HIV-1, this represents a rapid and effortless
adaptation to host immunity. NewKK10-specific CD8+ T cell clo-
notypes endowed with WT and Leu268Met recognition capacity
can then be recruited from the available repertoire. Indeed,
previous studies have also observed changes in the KK10-
specific CD8+ T cell repertoire associated with the emergence
of Leu268Met variants (Lichterfeld et al., 2007). This alternate
clonotypic repertoire is readily able to control HIV-1 replication,
as the appearance of the Leu268Met variant does not entail
concomitant increases in plasma viremia (Ammaranond et al.,
2011; Feeney et al., 2004; Goulder et al., 1997; Kelleher et al.,
2001). Nonetheless, this clonotypic restructuring is probably
not a trivial undertaking for an immune system already funda-
mentally compromised by the virus itself, in particular with
respect to the loss of memory CD4+ T cells and reduced naive
T cell production (Appay and Sauce, 2008; Douek et al., 2009).
In addition, WT and Leu268Met cross-reactive clonotypes can
be relatively complex to generate. This feature may help to
explain the diverse outcomes of HIV-1 infection across HLA-
B*2705+ cohorts, despite the overall protection associated with
carriage of this allele and the almost universal immunodomi-
nance of the KK10 epitope (Goulder and Watkins, 2008).
Eventually, though, the highly effective WT and Leu268Met
KK10-specific CD8+ T cell response drives the selection of
new variants, in particular the Arg264Lysmutation. This new viral
variant is more complex to produce because it requires the
compensatory Ser173Ala mutation. However, because of the
reduction in HLA-B*2705-KK10 peptide binding and presenta-
tion, this compound mutation renders the KK10-specific CD8+
T cell response obsolete and therefore represents the ultimate
viral adaptation in this system. Uncontrolled HIV-1 replication
and disease progression ensue (Almeida et al., 2007; Ammara-
nond et al., 2011; Feeney et al., 2004; Goulder et al., 1997; Kel-
leher et al., 2001).
The present work illuminates the mechanism that underpins
the control of HIV-1 replication in HLA-B*2705+ individuals,Immunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc. 433
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specific CD8+ T cell clonotypes (Chen et al., 2012). It seems likely
that the dual specificity TRBV6-5 TRBJ1-1 clonotypes were
selected from the available repertoire in response to the emer-
gence of Leu268Met variants. Remarkably, the absence of
detectable viral mutants in patients PrInf A and B suggests that
such clonotypes may have been elicited by very low-frequency
Leu268Met variants, which were subsequently suppressed
effectively to the extent that they remained below the limit
of detection with conventional subcloning and sequencing
approaches. The functional properties of C12C were consistent
with this possibility. In addition, a recent study has demonstrated
the feasibility of this scenario in another system (Henn et al.,
2012). Other clonotypes that recognize Leu268Met less sensi-
tively, as observed in PrInf C, maywell require higher frequencies
of the variant to be mobilized and will suppress HIV-1 replication
less effectively. The early prevalence of the Leu268Met variant
in cell-associated DNA from PrInf C and the progressive loss
of viral control observed in this patient are compatible with
these speculations. Accordingly, the kinetics of the continuous
competition between HIV-1 and CD8+ T cell-mediated adaptive
immunity are probably critical determinants of viral control and
pathogenesis.
Collectively, our findings suggest that the clonotypic nature of
the responding CD8+ T cell repertoire and the subtle selection of
TCRs conferring high-avidity recognition of both the WT and
variant epitopes underpin viremic control and limit the emer-
gence of escape mutations. Analysis of the C12C TCR in
complex with HLA-B*2705-KK10 elucidated the molecular basis
for effective dual recognition of the WT and Leu268Met epitopes
by TRBV6-5 TRBJ1-1 motif-bearing TCRs. Of note, the CDR1b
and CDR2b loop interactions were suboptimal with respect to
HLA-B*2705 binding, suggesting that biased TRBV6-5 gene
usage may reflect preferred TRBJ1-1 or TRAV14 gene pairing.
In keeping with this possibility, key residues involved in HLA-
B*2705-KK10 binding were encoded only by the TRAV14 gene.
This is consistent with a recent study highlighting the influence
of Va pairing on Vb recognition of the MHC-peptide complex
(Stadinski et al., 2011). These considerations also align well
with the observation that TRAV14 gene usage has been associ-
ated with high-avidity WT KK10-specific CD8+ T cell clonotypes
(Iglesias et al., 2011).
Other mutations at different positions within the KK10 epitope
(e.g., 4, 5, 7, or 9) have been reported and might affect TCR
recognition (Almeida et al., 2007; Ammaranond et al., 2011; Fee-
ney et al., 2004; Goulder et al., 1997; Kelleher et al., 2001; van
Bockel et al., 2011). These mutations are not associated with
enhanced viral replication, suggesting that the capacity of the
KK10-specific CD8+ T cell response to recruit cross-reactive
clonotypes from the available repertoire is not limited to the
Leu268Met variant. Indeed, the TRBV6-5 TRBJ1-1 clonotypes
described herein probably represent an array of clonally distrib-
uted CD8+ T cells that fulfill the same protective role against
HIV. This notion is supported by the observation of various
dominant cross-reactive KK10-specific CD8+ T cell clonotypes
in HLA-B*2705+ long-term nonprogressors or elite controllers
(van Bockel et al., 2011; Chen et al., 2012). Such adaptation
within the CD8+ T cell response probably impacts the durability
of immune control and biological outcome. More generally,434 Immunity 38, 425–436, March 21, 2013 ª2013 Elsevier Inc.immune adaptation to TCR-accessible mutations may become
limiting only in the case of highly restricted epitope-specific
repertoires (Price et al., 2004). However, in the case of mutations
that adversely impact MHC-I-peptide binding or Ag processing
(Goulder and Watkins, 2004), or even lead to epitope deletion
from the viral genome altogether (Price et al., 1997), the plasticity
of the CD8+ T cell response becomes irrelevant. These consider-
ations explain why themajority of described escapemutations in
HIV-1 infection operate to minimize epitope presentation.
The present study provides unprecedented insights into the
molecular arms race between HIV and CD8+ T cell immunity
within a single epitope specificity. Although the enormity of
such reciprocal adaptation across all potential epitopes is stag-
gering, the data reported here illuminate the precarious nature of
the incessant battle between host and virus that underlies the
apparent equilibrium established during the chronic phase of
HIV-1 infection.
EXPERIMENTAL PROCEDURES
Patients
Samples were obtained from asymptomatic HIV-1-infected HLA-B*2705+
patients enrolled in the French ANRS PRIMO cohorts. Antiretroviral therapy
was initiated upon evidence of disease progression (i.e., persistent uncon-
trolled viral replication or CD4+ T cell counts < 500 cells/mm3), occurring
6 years postinfection for PrInf A and B and 1.5 years postinfection for
PrInf C. The study was approved by the Institutional Review Board and Local
Ethics Committee of the Hoˆpital Pitie´-Salpeˆtrie`re, Paris. Peripheral blood
mononuclear cells (PBMCs) were separated from citrate anticoagulated blood
and cryo-preserved for subsequent studies. Plasma and cell-associated
HIV-1 gag sequencing was performed as described previously (Akahoshi
et al., 2012).
Viruses and CD8+ T Cell Clones
HIVNL4-3 was modified to express one or more mutations in p24 Gag
(Ser173Ala, Arg264Lys, and/or Leu268Met) via the GeneTailor site-directed
mutagenesis system (Invitrogen) and oligonucleotide primers as described
previously (Schneidewind et al., 2007). Viral stocks were generated by trans-
fection of HEK293T cells with 30 mg of plasmid DNA. Supernatants were
harvested 48 hr after transfection and frozen aliquots were stored at 80C.
The concentration of p24 Ag in viral stocks was measured by enzyme-linked
immunosorbent assay (HIV-1 p24 Ag ELISA kit; ZeptoMetrix). HIV-specific
CD8+ T cell clones were generated and maintained as described previously
(Almeida et al., 2009). In brief, single HLA-B*2705-KK10 tetramer+CD8+
T cells were sorted by flow cytometry and expanded in microtiter plates by
periodic stimulation in the presence of mixed irradiated allogeneic PBMCs,
phytohemagglutinin (PHA; 1 mg/ml), and recombinant human IL-2 (rhIL-2;
150 IU/ml) in RPMI 1640 medium supplemented with 5% human AB serum,
antibiotics, and L-glutamine.
Clonotype Analysis
Molecular analysis of TRB and TRA gene expression in KK10-specific
tetramer+CD8+ T cell populations isolated directly ex vivo by flow cytometry
was conducted via a template-switch anchored RT-PCR as described previ-
ously (Quigley et al., 2011). A similar approach was used to characterize
TRB and TRA gene expression in KK10-specific CD8+ T cell clones. In all
cases, TCR nomenclature was directly translated from the IMGT database
by web-based alignment of molecular TRB or TRA transcripts (IMGT, The
ImMunoGeneTics information system, http://www.imgt.org). The germline
alignments for the TRBV6-5 TRBJ1-1 clonotypes were determined to allow
for potential P-additions from the TRBD genes.
Functional Characterization of CD8+ T Cell Clones
Antigen sensitivity was assessed by measuring the peptide concentration
required to induce half-maximal responses (EC50) in cytolytic Cr
51 release
Immunity
Coadaptation of HIV and CD8+ T Cell Immunityassays with HLA-B*2705+ EBV-transformed B cell targets as described previ-
ously (Almeida et al., 2007, 2009). For functional profiling, CD8+ T cell clones
were incubated for 1 hr at 37C in the presence of aCD107a mAb and HLA-
B*2705+CD4+Tcells infected3days earlierwith titrated levels ofWTormutated
HIVNL4-3 virus; monensin (2.5 mg/ml; Sigma-Aldrich) and brefeldin A (5 mg/ml;
Sigma-Aldrich) were added for a further 5 hr. Staining for intracellular markers
and data analysis were performed as described previously (Almeida et al.,
2009). For HIV suppression assays, primary HLA-B*2705+ CD4+ T cells were
purified from PBMCs by positive magnetic bead selection (Miltenyi Biotec),
stimulated for 2 days with PHA (1 mg/ml), and cultured with 100 U/ml rhIL-2.
Seven days later, 105 cells/well were infected with titrated levels of viruses by
spinoculation (Iglesias et al., 2011) and mixed with CD8+ T cell clones at
different CD8+/CD4+ ratios. Cells were harvested at day 3 postinfection, then
stained for both CD4 and intracellular p24 to evaluate the elimination of HIV-
infected targets. The protocol for competitive viral selection assays is provided
in Supplemental Information online. Directly conjugatedmAbswere purchased
as follows: from BD Biosciences, aCD4-APCCy7, aCD107a-Cy5PE, aIL-2-
APC, aIFNg-Alexa700, and aTNFa-PECy7; from Caltag Laboratories, aCD8-
Alexa405; from R&D Systems, aMIP-1b-FITC; and from Beckman Coulter,
ap24-PE. The viability dye ViViD (Life Technologies) was used to eliminate
dead cells from flow cytometric analyses.
Protein Production and Crystallography
Soluble recombinant proteins for structural and binding studies were pro-
duced as described previously with minor modifications (Gras et al., 2009;
Iglesias et al., 2011; Price et al., 2005). Crystals of the C12C TCR in complex
with WT and Leu268Met HLA-B*2705-KK10 were grown by the hanging-
drop, vapor-diffusion method at 20C with a protein reservoir drop ratio of
1:1 and a concentration of 5 mg/ml in 10 mM Tris (pH 8), 150 mM NaCl. Crys-
tals grew in 24%PEG 3350 and 0.3MNa2SO4. Crystals of theWT and Leu268-
Met HLA-B*2705-KK10 complexes were grown by the same technique in
a mother liquor containing 16% PEG 8000 and 0.1 M MES (pH 7.0). Data
collection, processing, structure determination, refinement, and validation
were conducted with standard crystallography software. Details are provided
in Supplemental Information online.
Statistics
Groupmedians and distributions were compared by theMann-Whitney U-test.
p values less than 0.05 were considered significant.
ACCESSION NUMBERS
The atomic coordinates and structure factors were deposited in the Protein
Data Bank with the following accession codes: 4G8G for the C12C TCR in
complex with WT HLA-B*2705-KK10, 4G9F for the C12C TCR in complex
with Leu268Met HLA-B*2705-KK10, 4G9D for WT HLA B*2705-KK10, and
4G8I for Leu268Met HLA B*2705-KK10.
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six figures, and two tables and can be found with this article online at http://
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